Together, these preclinical data suggest that a short-term prophylactic treatment with inhibitors blocking Jak2-STAT5 signaling may lower breast cancer risk for women who have had a late-age first pregnancy and have already completed lactation. The gene discussed is JAK2; the disease is breast carcinoma.